OKYO Pharma Corporation has disclosed that OK-101 has met its primary efficacy benchmarks in Phase 2 human trials, demonstrating statistical relevance in treating dry eye condition.

Novartis' Scemblix® outperforms traditional therapy in achieving significant molecular remission in a Phase III study involving newly diagnosed chronic myeloid leukemia patients.

Caliway Reveals US FDA Approval for Phase II Trial Application of CBL-514, a Sham-Controlled Study Aiming to Address Dercum's Syndrome.

UCB has revealed that the European Commission has sanctioned the use of RYSTIGGO (rozanolixizumab) for treating generalized myasthenia gravis in adult patients across Europe.

OBI Pharma has disclosed that the FDA has given its approval for a Phase 1/2 clinical trial application concerning OBI-992, a TROP2 antibody-drug conjugate.

Asklepios BioPharmaceutical, Inc., a wholly-owned subsidiary of Bayer AG, has launched Phase II of the GenePHIT trial to assess the effectiveness of its gene therapy drug AB-1002 (NAN-101) for congestive heart failure.

Sana Biotech Reveals US Regulatory Approval for Experimental Drug SC262, an Engineered Immune-resistant, Targeted CD22 Allo CAR T Cell Treatment, Aimed at Individuals Suffering from Recurring or Resistant Types of B-cell Cancer.

Boston Pharmaceuticals Unveils Research at the 2024 NASH-TAG Showing Sustained Low Immune Reaction to their Extended-release FGF21 Mimic, BOS-580, in MASH Management.

Ligand Pharmaceuticals Inc. has announced FDA approval for ZELSUVMI™ (berdazimer topical gel, 10.3%), now approved to treat molluscum contagiosum in adults and children aged 1 and older.

BioPharma Accord, Inc. reports the U.S. FDA has greenlit their application for a license regarding their proposed biosimilar to STELARA®, named DMB-3115.

Innate Pharma has been given the green light by the FDA to resume its Lacutamab Clinical Program after the previous partial clinical hold was removed.

Avenzo Therapeutics has disclosed the promising clinical phase CDK2 inhibitor known as AVZO-021, originally developed by Allorion Therapeutics.